Last reviewed · How we verify
Intravenous Oxytocin
Intravenous oxytocin is a synthetic peptide hormone that binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown during lactation.
Intravenous oxytocin is a synthetic peptide hormone that binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown during lactation. Used for Labor induction, Augmentation of labor, Prevention or treatment of postpartum hemorrhage.
At a glance
| Generic name | Intravenous Oxytocin |
|---|---|
| Also known as | IV Product, Pitocin, Oxytocin-Grindeks |
| Sponsor | University of Wisconsin, Madison |
| Drug class | Peptide hormone |
| Target | Oxytocin receptor (OXTR) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics and Gynecology |
| Phase | Phase 3 |
Mechanism of action
Oxytocin is a naturally occurring neuropeptide that acts on G-protein coupled oxytocin receptors located on uterine smooth muscle and mammary gland myoepithelial cells. When administered intravenously, it triggers rhythmic uterine contractions and facilitates lactation by promoting milk ejection. The drug has been used clinically for decades in obstetrics and gynecology.
Approved indications
- Labor induction
- Augmentation of labor
- Prevention or treatment of postpartum hemorrhage
- Promotion of milk letdown during lactation
Common side effects
- Uterine hyperstimulation
- Nausea
- Vomiting
- Headache
- Water intoxication (with prolonged high-dose infusion)
- Hypertension
Key clinical trials
- The Stimulation To Induce Mothers Study (PHASE4)
- Efficacy of Intravenous Oxytocin to Speed Recovery After THA (PHASE2)
- PGE2 Followed by Oxytocin vs Oxytocin in Term PROM (POXY-PROM) (NA)
- Effects Of Intravenous Oxytocin On Peripheral Sensory Afferents Using Microneurography (PHASE2)
- Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage (PHASE4)
- Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain (PHASE2)
- Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention (NA)
- A Randomized Controlled Trial to Test the Effects Oxytocin and Vibration Have on Heat Pain Threshold After UV-B Burn (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Oxytocin CI brief — competitive landscape report
- Intravenous Oxytocin updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI